Insider Selling: Kevin Conroy Sells 26,379 Shares of EXACT Sciences Corp. Stock (EXAS)
EXACT Sciences Corp. (NASDAQ:EXAS) CEO Kevin Conroy sold 26,379 shares of the stock on the open market in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $11.96, for a total value of $315,492.84. Following the completion of the transaction, the chief executive officer now directly owns 123,707 shares in the company, valued at approximately $1,479,536. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of EXACT Sciences Corp. (NASDAQ:EXAS) traded up 2.20% on Friday, hitting $12.08. 1,733,041 shares of the company’s stock traded hands. EXACT Sciences Corp. has a one year low of $6.93 and a one year high of $14.70. The stock’s 50-day moving average is $11.93 and its 200-day moving average is $12.22. The company’s market cap is $856.7 million.
EXACT Sciences Corp. (NASDAQ:EXAS) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. The company had revenue of $1.00 million for the quarter, compared to the consensus estimate of $1.02 million. During the same quarter last year, the company posted ($0.21) earnings per share. EXACT Sciences Corp.’s revenue was up .0% compared to the same quarter last year.
Several analysts have recently commented on the stock. Analysts at Maxim Group reiterated a “sell” rating on shares of EXACT Sciences Corp. in a research note to investors on Tuesday, October 29th. Analysts at Wedbush upgraded shares of EXACT Sciences Corp. from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday, October 16th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $17.38.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.